Green Cross (Japan)

Green Cross Corporation (株式会社ミドリ十字; Kabushiki Gaisha Midori Jūji) was one of the premier pharmaceutical companies in Japan. The company merged into Yoshitomi Pharmaceutical Co., Ltd. (吉富製薬株式会社) on April 1, 1998, and renamed to Welfide Corporation (ウェルファイド株式会社) on April 1, 2000. Finally Welfide Corp. and Mitsubishi-Tokyo Pharmaceutical Inc. (三菱東京製薬株式会社) were merged to form Mitsubishi Pharma Corporation (三菱ウェルファーマ株式会社) on October 1, 2001.

Additional recommended knowledge

What is the Correct Way to Check Repeatability in Balances?

Correct Test Weight Handling Guide: 12 Practical Tips

Essential Laboratory Skills Guide

Green Cross was founded in 1950 as Japan's first commercial blood bank and became a diversified international pharmaceutical company producing ethical drugs for delivery or administration by doctors and healthcare workers. Its founders included war criminals such as Kitano Masaji who performed torture and human experimentation in Unit 731 of the Japanese military during World War II.

Its products were extensively used in the treatments of a wide range of ailments. As well as supplying whole blood for transfusions, Green Cross was also active in developing blood derivative products such as coagulation factors, immunoglobulin and albumin. In the mid 1960's, it expanded into the non-plasma sector. Cardiovascular agents, coagulation/fibrinolytic agents, immunological agents, anti-inflammatory agents, albumin-based agents, blood plasma components and parenteral nutrition accounted for 71% of fiscal 1998 unconsolidated revenues; wholesale of diagnostic reagents, 14% and other, 15%. Unconsolidated revenues accounted for 59.5% of fiscal 1998 consolidated revenues. The company had eleven consolidated subsidiaries, three each in the United States and Japan, and one each in Germany, the United Kingdom, Barbados, China and Hong Kong. Overseas sales accounted for 41.9% of fiscal 1998 consolidated revenues.

See also

• HIV-tainted blood scandal (Japan)